-
EP3766916
European procedure
Extract from the Register of European Patents
EP About this file: EP3766916
| EP3766916 - NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.08.2023 Database last updated on 08.04.2026 | |
| Former | The patent has been granted Status updated on 26.08.2022 | ||
| Former | Grant of patent is intended Status updated on 20.06.2022 | ||
| Former | Examination is in progress Status updated on 18.02.2022 | ||
| Former | Request for examination was made Status updated on 18.12.2020 | Most recent event Tooltip | 27.06.2024 | Change - lapse in a contracting state State(s) deleted from list of lapses: AL | published on 31.07.2024 [2024/31] | Applicant(s) | For all designated states Acuitas Therapeutics Inc. 6190 Agronomy Road Suite 402 University of British Columbia - KETR Vancouver, British Columbia V6T 1W5 / CA | [2021/03] | Inventor(s) | 01 /
ANSELL, Steven, M. 201 - 2010 West 8th Avenue Vancouver, British Columbia V6J 1W5 / CA | 02 /
DU, Xinyao 9580 Snowdon Avenue Richmond, British Columbia V7A 2M1 / CA | [2021/03] | Representative(s) | Grünecker Patent- und Rechtsanwälte PartG mbB Leopoldstraße 4 80802 München / DE | [2021/03] | Application number, filing date | 20195502.8 | 05.06.2015 | [2021/03] | Priority number, date | US201462016839P | 25.06.2014 Original published format: US 201462016839 P | [2021/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3766916 | Date: | 20.01.2021 | Language: | EN | [2021/03] | Type: | B1 Patent specification | No.: | EP3766916 | Date: | 28.09.2022 | Language: | EN | [2022/39] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 08.12.2020 | Classification | IPC: | C08G65/325 | [2021/03] | CPC: |
A61K9/1272 (EP,IL,US);
C07C229/24 (IL,US);
A61K38/4846 (EP,IL,US);
A61K47/18 (EP,IL,US);
A61K47/22 (EP,IL,US);
A61K47/24 (IL,US);
A61K47/28 (IL,US);
A61K48/0041 (IL,US);
A61P43/00 (EP,IL);
C07C219/06 (EP,IL,US);
C07C219/08 (EP,IL,US);
C07C219/10 (EP,IL,US);
C07C227/16 (IL,US);
C07C229/16 (EP,IL,US);
C07C235/06 (IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/03] | Title | German: | NEUARTIGE LIPIDE UND LIPIDNANOPARTIKELFORMULIERUNGEN ZUR FREISETZUNG VON NUKLEINSÄUREN | [2021/03] | English: | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | [2021/03] | French: | NOUVEAUX LIPIDES ET FORMULATIONS NANOPARTICULAIRES LIPIDIQUES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES | [2021/03] | Examination procedure | 10.09.2020 | Examination requested [2021/03] | 20.07.2021 | Amendment by applicant (claims and/or description) | 17.02.2022 | Despatch of a communication from the examining division (Time limit: M04) | 01.04.2022 | Reply to a communication from the examining division | 21.06.2022 | Communication of intention to grant the patent | 17.08.2022 | Fee for grant paid | 17.08.2022 | Fee for publishing/printing paid | 17.08.2022 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP15730023.7 / EP3160938 | Divisional application(s) | EP22197899.2 / EP4148083 | Opposition(s) | 29.06.2023 | No opposition filed within time limit [2023/36] | Fees paid | Renewal fee | 10.09.2020 | Renewal fee patent year 03 | 10.09.2020 | Renewal fee patent year 04 | 10.09.2020 | Renewal fee patent year 05 | 10.09.2020 | Renewal fee patent year 06 | 28.06.2021 | Renewal fee patent year 07 | 27.06.2022 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | deleted | [2024/31] |
| Former [2023/29] | AL | 28.09.2022 | Documents cited: | Search | [E] WO2016176330 (UNIV PENNSYLVANIA et al.) | [A] ANSELL S. ET AL: "Applications of oligo(14-amino-3,6,9,-tetraoxatetradecanoic acid) lipid conjugates as sterioc barrier molecules in liposomal formulations", BIOCONJUGATE CHEMISTRY, vol. 10, 1999, pages 653 - 666, XP002801230 | [A] LEE J.B. ET AL: "Lipid nanoparticle siRNA systems for silencing the adrogen receptor in human prostrate cancer in vivo", INTERNATIONAL JOURNAL OF CANCER, vol. 131, 2011, pages E781 - E790, XP002801231 | [A] MARCHI-ARTZNER V ET AL: "Adhesion of Arg-Gly-Asp ( RGD ) Peptide Vesicles onto an Integrin Surface: Visualization of the Segregation of RGD Ligands into the Adhesion Plaques by Fluorescence", LANGMUIR, AMERICAN CHEMICAL SOCIETY, US, vol. 19, no. 3, 1 February 2003 (2003-02-01), pages 835 - 841, XP002326372, ISSN: 0743-7463, DOI: 10.1021/LA026227K DOI: http://dx.doi.org/10.1021/la026227k | Examination | FRISCH B ET AL: "A NEW TRIANTENNARY GALACTOSE-TARGETED PEGYLATED GENE CARRIER, CHARACTERIZATION OF ITS COMPLEX WITH DNA, AND TRANSFECTION OF HEPATOMA CELLS", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 15, no. 4, 1 July 2004 (2004-07-01), pages 754 - 764, XP001236861, ISSN: 1043-1802, DOI: 10.1021/BC049971K DOI: http://dx.doi.org/10.1021/bc049971k | by applicant | US2012251618 | US6197553 | US2004142025 | US2007042031 | WO2013016058 | WO2013086373 | US2010022614 | US201462016839 | LINPINSEL, J.LCONN, G.L., GENERAL PROTOCOLS FOR PREPARATION OF PLASMID DNA TEMPLATE | BOWMAN, J.C.AZIZI, B.LENZ, T.K.RAY, P.WILLIAMS, L.D.: "RNA in vitro transcription and RNA purification by denaturing PAGE in Recombinant and in vitro RNA syntheses Methods", vol. 941, 2012, HUMANA PRESS, article "RNA in vitro transcription and RNA purification by denaturing PAGE" | LOSICK, R.: "In vitro transcription", ANN REV BIOCHEM, vol. 41, 1972, pages 409 - 46, XP055712693, DOI: 10.1146/annurev.bi.41.070172.002205 DOI: http://dx.doi.org/10.1146/annurev.bi.41.070172.002205 | KAMAKAKA, R. T.KRAUS, W. L.: "In Vitro Transcription", CURRENT PROTOCOLS IN CELL BIOLOGY, vol. 2, 2001 | SEMPLE ET AL., NATURE BIOTECHNOLOGY, vol. 703, 2010, pages 172 - 176 | BRUNELLE, J.L.GREEN, R., IN VITRO TRANSCRIPTION FROM PLASMID OR PCR-AMPLIFIED DNA, METHODS IN ENZYMOLOGY, vol. 530, 2013, pages 101 - 114 | LUKAVSKY, P.J.PUGLISI, J.D.: "Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides", RNA, vol. 10, 2004, pages 889 - 893 | KARIKO, K.MURAMATSU, H.LUDWIG, J.WEISSMAN, D.: "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA", NUCL ACID RES, vol. 39, 2011, pages e142, XP002758752, DOI: 10.1093/nar/gkr695 DOI: http://dx.doi.org/10.1093/nar/gkr695 | GRUDZIEN-NOGALSKA, E.KOWALSKA, J.SU, W.KUHN, A.N.SLEPENKOV, S.V.DARYNKIEWICZ, E.SAHIN, U.JEMIELITY, J.RHOADS, R.E.: "Methods in Molecular Biology", vol. 288, 2005, HUMANA PRESS, article "In vitro transcription of long RNA containing modified nucleosides in Synthetic Messenger RNA and Cell Metabolism Modulation" | BERNSTEIN, P.ROSS, J.: "Poly (A), poly (A) binding protein and the regulation of mRNA stability", TRENDS BIO SCI, vol. 14, 1989, pages 373 - 377, XP023669459, DOI: 10.1016/0968-0004(89)90011-X DOI: http://dx.doi.org/10.1016/0968-0004(89)90011-X | GUHANIYOGI, J.BREWER, G.: "Regulation of mRNA stability in mammalian cells", GENE, vol. 265, 2001, pages 11 - 23, XP004230718, DOI: 10.1016/S0378-1119(01)00350-X DOI: http://dx.doi.org/10.1016/S0378-1119(01)00350-X | DREYFUS, M.REGNIER, P.: "The poly (A) tail of mRNAs: Bodyguard in eukaryotes, scavenger in bacteria", CELL, vol. 111, 2002, pages 611 - 613 | KARIKO, K.WEISSMAN, D.: "Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development", CURR OPIN DRUG DISCOV DEVEL, vol. 10, 2007, pages 523 - 532, XP009154595 | KARIKO, K.MURAMATSU, H.WELSH, F.A.LUDWIG, J.KATO, H.AKIRA, S.WEISSMAN, D.: "Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability", MOL THER, vol. 16, 2008, pages 1833 - 1840 | "Oligonucleotide synthesis: a practical approach, Oxford [Oxfordshire], Washington, D.C.", 1984, IRL PRESS | HEILIG, J.ELBING, K. L.BRENT, R: "Large-Scale Preparation of Plasmid DNA", CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vol. 41, 2001 | ROZKOV, A.LARSSON, B.GILLSTROM, S.BJORNESTEDT, R.SCHMIDT, S. R.: "Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture", BIOTECHNOL. BIOENG., vol. 99, 2008, pages 557 - 566, XP055734376, DOI: 10.1002/bit.21603 DOI: http://dx.doi.org/10.1002/bit.21603 | BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081 | OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608 | ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98 | SEMPLE, S.C. ET AL., ADV. DRUG DELIV REV, vol. 32, 1998, pages 3 - 17 | HAFEZ, I.M. ET AL., GENE THER, vol. 8, 2001, pages 1188 - 1196 | BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24 | HIGUCHI, T. ET AL., A.C.S. SYMPOSIUM SERIES, vol. 14 | "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS | "Remington: The Science and Practice of Pharmacy", 2000 | GREEN, T.W.P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY | "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", December 2000, WILEY | JAYARAMAN ET AL., ANGEWANDTE CHEMIE, vol. 51, no. 34, 2012, pages 8529 - 8533 |